Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiology and Therapy
Published in: Cardiology and Therapy 2/2021

Open Access 01-12-2021 | Warfarin | Review

Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease

Authors: Eman Abdelghani, Clifford L. Cua, Jean Giver, Vilmarie Rodriguez

Published in: Cardiology and Therapy | Issue 2/2021

Login to get access

Abstract

Thrombosis is one of the most frequent complications affecting children with congenital heart disease (CHD). Palliative and reparative cardiac surgeries are some of the main players contributing to the thrombosis risk in this patient population. Additional risk factors related to the CHD itself (e.g., cardiac dysfunction, arrhythmias, and polycythemia in cyanotic cardiac disorders) can contribute to thrombogenicity alone or combined with other factors. Thrombotic complications have been recognized as a significant cause of morbidity and mortality in this patient population. Here, we provide an overview of the pathophysiology and risk factors for thrombosis as well as the indications for and use of different anticoagulation, antiplatelet, and thrombolytic agents. In addition, we describe some of most common thrombotic complications and their management in the pediatric CHD population.
Literature
1.
Best KE, Rankin J. Long-term survival of individuals born with congenital heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2016;5:e002846.PubMedPubMedCentralCrossRef
2.
Petrini JR, Broussard CS, Gilboa SM, Lee KA, Oster M, Honein MA. Racial differences by gestational age in neonatal deaths attributable to congenital heart defects—United States, 2003–2006. MMWR Morb Mortal Wkly Rep. 2010;59:1208–11.
3.
Oster ME, Lee KA, Honein MA, Riehle-Colarusso T, Shin M, Correa A. Temporal trends in survival among infants with critical congenital heart defects. Pediatrics. 2013;131:e1502–8.PubMedCrossRef
4.
Giglia TM, Witmer C, Procaccini DE, Byrnes JW. Pediatric Cardiac Intensive Care Society 2014 consensus statement: pharmacotherapies in cardiac critical care anticoagulation and thrombolysis. Pediatr Crit Care Med. 2016;17:S77–88.PubMedCrossRef
5.
Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood. 1994;83:1251–7.PubMedCrossRef
6.
van Ommen CH, Heijboer H, Büller HR, Hirasing RA, Heijmans HSA, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr. 2001;139:676–81.PubMedCrossRef
7.
Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr Res. 2000;47:763–6.PubMedCrossRef
8.
Kim S-J, Sabharwal S. Risk factors for venous thromboembolism in hospitalized children and adolescents: A systemic review and pooled analysis. J Pediatr Orthop Part B. 2014;23:389–93.CrossRef
9.
Ören H, Devecioğlu Ö, Kemahli S, et al. Analysis of pediatric thrombotic patients in Turkey. Pediatr Hematol Oncol. 2004;21:573–83.PubMedCrossRef
10.
Manlhiot C, Menjak IB, Brandao LR, et al. Risk, clinical features, and outcomes of thrombosis associated with pediatric cardiac surgery. Circulation. 2011;124:1511–9.PubMedCrossRef
11.
Silvey M, Hall M, Bilynsky E, Carpenter SL. Increasing rates of thrombosis in children with congenital heart disease undergoing cardiac surgery. Thromb Res. 2018;162:15–21.PubMedCrossRef
12.
Gruenwald CE, Manlhiot C, Crawford-Lean L, et al. Management and monitoring of anticoagulation for children undergoing cardiopulmonary bypass in cardiac surgery. J Extra Corpor Technol. 2010;42:9.PubMedPubMedCentral
13.
Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95:362–72.PubMedCrossRef
14.
Andrew M, Monagle PT, Brooker L. Thromboembolic complications during infancy and childhood. Shelton: PMPH USA; 2000.
15.
Alioglu B, Avci Z, Tokel K, Atac FB, Ozbek N. Thrombosis in children with cardiac pathology: analysis of acquired and inherited risk factors. Blood Coagul Fibrinolysis. 2008;19:294–304.PubMedCrossRef
16.
Coon PD, Rychik J, Novello RT, Ro PS, Gaynor JW, Spray TL. Thrombus formation after the Fontan operation. Ann Thorac Surg. 2001;71:1990–4.PubMedCrossRef
17.
Ehrenforth S, Junker R, Koch HG, et al. Multicentre evaluation of combined prothrombotic defects associated with thrombophilia in childhood. Eur J Pediatr. 1999;158:S97–104.PubMedCrossRef
18.
Ong BC, Zimmerman AA, Zappulla DC, Neufeld EJ, Burrows FA. Prevalence of factor V Leiden in a population of patients with congenital heart disease. Can J Anaesth. 1998;45:1176–80.PubMedCrossRef
19.
Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999(Suppl 3);25:5–16.PubMed
20.
21.
Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975;250:8883–8.PubMedCrossRef
22.
Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e737S–801S.PubMedPubMedCentralCrossRef
23.
Liveris A, Bello RA, Friedmann P, et al. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2014;15:e72–9.PubMedCrossRef
24.
Samuel S, Allison TA, Sharaf S, et al. Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study. J Clin Pharm Ther. 2016;41:499–502.PubMedCrossRef
25.
Chan AK, Black L, Ing C, Brandão LR, Williams S. Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res. 2008;122:135–6.PubMedCrossRef
26.
Newall F, Johnston L, Ignjatovic V, Monagle P. Unfractionated heparin therapy in infants and children. Pediatrics. 2009;123(3):e510–8.PubMedCrossRef
27.
McDonald MM, Jacobson LJ, Hay WW Jr, Hathaway WE. Heparin clearance in the newborn. Pediatr Res. 1981;15:1015–8.PubMedCrossRef
28.
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S–43S.PubMedPubMedCentralCrossRef
29.
Risch L, Huber AR, Schmugge M. Diagnosis and treatment of heparin-induced thrombocytopenia in neonates and children. Thromb Res. 2006;118:123–35.PubMedCrossRef
30.
Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108:258s–75s.PubMedCrossRef
31.
Hirsh J, Levine MN. Low molecular weight heparin: laboratory properties and clinical evaluation. A review. Eur J Surg Suppl Acta Chir Suppl. 1994;571:9–22.
32.
Royston D. 45—anticoagulant and antiplatelet therapy. In: Hemmings HC, Egan TD, editors. Pharmacology and physiology for anesthesia (second edition). Philadelphia: Elsevier; 2019. p. 870–94.CrossRef
33.
Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr. 2000;136:439–45.PubMedCrossRef
34.
Bauman ME, Belletrutti MJ, Bajzar L, et al. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels. Thromb Haemost. 2009;101:86–92.PubMedCrossRef
35.
Vakil NH, Kanaan AO, Donovan JL. Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther. 2012;17:12–30.PubMedPubMedCentral
36.
Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332:1330–5.PubMedCrossRef
37.
Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. FondaKIDS: A prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011;57:1049–54.PubMedCrossRef
38.
Paolucci F, Frasa H, Van Aarle F, et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab. 2003;49:451–60.PubMed
39.
Schindewolf M, Steindl J, Beyer-Westendorf J, et al. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)–findings from the GerHIT multi-centre registry study. Thromb Res. 2014;134:29–35.PubMedCrossRef
40.
Tokgoz H, Caliskan U, Demir M. Successful use of fondaparinux in a child with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 2012;23:769–71.PubMedCrossRef
41.
Andrew M, Marzinotto V, Brooker LA, et al. Oral anticoagulation therapy in pediatric patients: a prospective study. Thromb Haemost. 1994;71:265–9.PubMedCrossRef
42.
Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest. 2008;133:160s–98s.PubMedCrossRef
43.
Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198:198–9.PubMedCrossRef
44.
Jansma B, Montgomery J, Dietrich S, Mixon MA, Peksa GD, Faine B. Emergent warfarin reversal with fixed-dose 4-factor prothrombin complex concentrate. Ann Pharmacother. 2020;54:1090–5.PubMedCrossRef
45.
Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40.PubMedCrossRef
46.
Yarbrough PM, Varedi A, Walker A, Rondina MT. Argatroban dose reductions for suspected heparin-induced thrombocytopenia complicated by Child-Pugh class C liver disease. Ann Pharmacother. 2012;46:e30.PubMedPubMedCentralCrossRef
47.
Oschman A. Survey results: characterization of direct thrombin inhibitor use in pediatric patients. J Pediatr Pharmacol Ther. 2014;19(1):10–5.PubMedPubMedCentral
48.
Moffett BS, Teruya J. Trends in parenteral direct thrombin inhibitor use in pediatric patients: analysis of a large administrative database. Arch Pathol Lab Med. 2014;138:1229–32.PubMedCrossRef
49.
Zaleski KL, DiNardo JA, Nasr VG. Bivalirudin for pediatric procedural anticoagulation: a narrative review. Anesth Analg. 2019;128:43–55.PubMedCrossRef
50.
Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol. 2006;28:4–10.PubMedCrossRef
51.
Brandão LR, Albisetti M, Halton J, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. Blood. 2020;135:491–504.PubMedPubMedCentralCrossRef
52.
Payne RM, Burns KM, Glatz AC, et al. A multi-national trial of a direct oral anticoagulant in children with cardiac disease: design and rationale of the Safety of ApiXaban On Pediatric Heart disease On the preventioN of Embolism (SAXOPHONE) study. Am Heart J. 2019;217:52–63.PubMedPubMedCentralCrossRef
53.
Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.PubMedCrossRef
54.
Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020;18:1672–85.PubMedCrossRef
55.
Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019;6:e500–9.PubMedCrossRef
56.
57.
Giglia TM, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease. Circulation. 2013;128:2622–703.PubMedCrossRef
58.
Roach ES, Golomb MR, Adams R, et al. Management of stroke in infants and children: a scientific statement from a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke. 2008;39:2644–91.PubMedCrossRef
59.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–85.PubMedCrossRef
60.
Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601–6.PubMedCrossRef
61.
62.
Fox CK, Sidney S, Fullerton HJ. Community-based case–control study of childhood stroke risk associated with congenital heart disease. Stroke. 2015;46:336–40.PubMedCrossRef
63.
Domi T, Edgell DS, McCrindle BW, et al. Frequency, predictors, and neurologic outcomes of vaso-occlusive strokes associated with cardiac surgery in children. Pediatrics. 2008;122:1292–8.PubMedCrossRef
64.
Kumar K. Neurological complications of congenital heart disease. Indian J Pediatr. 2000;67:287–91.PubMedCrossRef
65.
Sun M-S, Jin H, Sun X, et al. Free radical damage in ischemia-reperfusion injury: an obstacle in acute ischemic stroke after revascularization therapy. Oxid Med Cell Longev. 2018;2018:3804979.PubMedPubMedCentralCrossRef
66.
Jonas RA. Neurological protection during cardiopulmonary bypass/deep hypothermia. Pediatr Cardiol. 1998;19:321–30.PubMedCrossRef
67.
Mahle WT, Tavani F, Zimmerman RA, et al. An MRI study of neurological injury before and after congenital heart surgery. Circulation. 2002;106:I-109–14.CrossRef
68.
Miller SP, McQuillen PS, Hamrick S, et al. Abnormal brain development in newborns with congenital heart disease. N Engl J Med. 2007;357:1928–38.PubMedCrossRef
69.
Shah R, Nayyar M, Jovin IS, et al. Device closure versus medical therapy alone for patent foramen ovale in patients with cryptogenic stroke: a systematic review and meta-analysis. Ann Intern Med. 2018;168:335–42.PubMedCrossRef
70.
Baumgartner H, De Backer J. The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020. Eur Heart J. 2020;41:4153–4.PubMedCrossRef
71.
Meier B, Blaauw Y, Khattab AA, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. EuroIntervention. 2015;10:1109–25.PubMedCrossRef
72.
Mehta R, Lee KJ, Chaturvedi R, Benson L. Complications of pediatric cardiac catheterization: a review in the current era. Catheter Cardiovasc Interv. 2008;72:278–85.PubMedCrossRef
73.
Brotschi B, Hug MI, Kretschmar O, Rizzi M, Albisetti M. Incidence and predictors of cardiac catheterisation-related arterial thrombosis in children. Heart. 2015;101:948–53.PubMedCrossRef
74.
Bratincsák A, Moore JW, El-Said HG. Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: a single center experience. Catheter Cardiovasc Interv. 2013;82:782–5.PubMedCrossRef
75.
Laurin S, Lundström NR. Venous thrombosis after cardiac catheterization in infants. Acta Radiol. 1987;28:241–6.PubMedCrossRef
76.
Ruud E, Natvig S, Holmstrøm H, Wesenberg F. Low prevalence of femoral venous thrombosis after cardiac catheterizations in children: a prospective study. Cardiol Young. 2002;12:513–8.PubMedCrossRef
77.
Hanslik A, Kitzmüller E, Thom K, et al. Incidence of thrombotic and bleeding complications during cardiac catheterization in children: comparison of high-dose vs. low-dose heparin protocols. J Thromb Haemost. 2011;9:2353–60.PubMedCrossRef
78.
Celermajer DS, Robinson J, Taylor J. Vascular access in previously catheterised children and adolescents: a prospective study of 131 consecutive cases. Heart. 1993;70:554–7.CrossRef
79.
Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2:3292–316.PubMedPubMedCentralCrossRef
80.
Massicotte MP, Dix D, Monagle P, Adams M, Andrew M. Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. J Pediatr. 1998;133:770–6.PubMedCrossRef
81.
Streif W, Andrew ME. Venous thromboembolic events in pediatric patients: diagnosis and management. Hematol Oncol Clin North Am. 1998;12:1283–312.PubMedCrossRef
82.
Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest. 2002;121:877–905.PubMedCrossRef
83.
Yang JY, Williams S, Brandão LR, Chan AK. Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approach. Blood Coag Fibrinol. 2010;21:301–7.CrossRef
84.
Bendaly EA, Batra AS, Ebenroth ES, Hurwitz RA. Outcome of cardiac thrombi in infants. Pediatr Cardiol. 2008;29:95–101.PubMedCrossRef
85.
Shaffer KM, Mullins CE, Grifka RG, et al. Intravascular stents in congenital heart disease: short- and long-term results from a large single-center experience. J Am Coll Cardiol. 1998;31:661–7.PubMedCrossRef
86.
Feltes TF, Bacha E, Beekman RH, 3rd, et al. Indications for cardiac catheterization and intervention in pediatric cardiac disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2607–52.PubMedCrossRef
87.
Al Jubair KA, Al Fagih MR, Al Jarallah AS, et al. Results of 546 Blalock–Taussig shunts performed in 478 patients. Cardiol Young. 1998;8:486–90.PubMedCrossRef
88.
Li JS, Yow E, Berezny KY, et al. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference? Circulation. 2007;116:293–7.PubMedCrossRef
89.
Fenton KN, Siewers RD, Rebovich B, Pigula FA. Interim mortality in infants with systemic-to–pulmonary artery shunts. Ann Thorac Surg. 2003;76:152–6.PubMedCrossRef
90.
91.
Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-Hernandez K. Prosthetic heart valve thrombosis: pathogenesis, diagnosis and management. Int J Cardiol. 2006;110:1–6.PubMedCrossRef
92.
Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68:2670–89.PubMedCrossRef
93.
Lengyel M, Fuster V, Keltai M, et al. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. J Am Coll Cardiol. 1997;30:1521–6.PubMedCrossRef
94.
Gürsoy MO, Kalçık, M, Yesin M, et al. A global perspective on mechanical prosthetic heart valve thrombosis: Diagnostic and therapeutic challenges. Anatol J Cardiol. 2016;16:980.PubMedPubMedCentral
95.
Gündüz S, Kalçık M, Gürsoy MO, Güner A, Özkan M. Diagnosis, treatment & management of prosthetic valve thrombosis: the key considerations. Expert Rev Med Dev. 2020;17:209–21.CrossRef
96.
Özkan M, Gündüz S, Gürsoy OM, et al. Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: the Ultra-slow PROMETEE trial. Am Heart J. 2015;170:409–18.e1.PubMedCrossRef
97.
Khajali Z, Mohammadzadeh S, Maleki M, et al. Fibrinolytic therapy for mechanical pulmonary valve thrombosis. Pediatr Cardiol. 2015;36:171–6.PubMedCrossRef
98.
Ramos AI, Ramos RF, Togna DJ, et al. Fibrinolytic therapy for thrombosis in cardiac valvular prosthesis short and long term results. Arq Bras Cardiol. 2003;81:393–8.PubMedCrossRef
99.
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e1159–95.PubMedCrossRef
100.
De Caterina R, Husted S, Wallentin L, et al. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:769–86.PubMedCrossRef
101.
Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e576S–600S.PubMedPubMedCentralCrossRef
102.
RJ IJ, Slieker MG, Hazekamp MG, et al. Mitral valve replacement with the 15-mm mechanical valve: a 20-year multicenter experience. Ann Thorac Surg. 2020;110:956–61.CrossRef
103.
Kiper C, Cua CL, Baker P, 3rd, McConnell P. Mitral valve replacement in pediatrics using an extracellular matrix cylinder valve: a case series. Pediatr Cardiol. 2020;41:1458–65.PubMedCrossRef
104.
Gillespie MJ, Benson LN, Bergersen L, et al. Patient selection process for the harmony transcatheter pulmonary valve early feasibility study. Am J Cardiol. 2017;120:1387–92.PubMedCrossRef
105.
Quinonez LG, Breitbart R, Tworetsky W, Lock JE, Marshall AC, Emani SM. Stented bovine jugular vein graft (Melody valve) for surgical mitral valve replacement in infants and children. J Thorac Cardiovasc Surg. 2014;148:1443–9.PubMedCrossRef
106.
Manlhiot C, Brandao LR, Kwok J, et al. Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation. J Pediatr. 2012;161:513–19 e3.PubMedCrossRef
107.
108.
Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133:887S–968S.PubMedCrossRef
109.
Monagle P. Thrombosis in children with BT shunts, Glenns and Fontans. Prog Pediatr Cardiol. 2005;21:17–21.CrossRef
110.
Wells WJ, Yu RJ, Batra AS, Monforte H, Sintek C, Starnes VA. Obstruction in modified Blalock shunts: a quantitative analysis with clinical correlation. Ann Thorac Surg. 2005;79:2072–6.PubMedCrossRef
111.
Procelewska M, Kolcz J, Januszewska K, Mroczek T, Malec E. Coagulation abnormalities and liver function after hemi-Fontan and Fontan procedures—the importance of hemodynamics in the early postoperative period. Eur J Cardiothorac Surg. 2007;31:866–72.PubMedCrossRef
112.
Cheung EW, Chay GW, Ma ES, Cheung YF. Systemic oxygen saturation and coagulation factor abnormalities before and after the fontan procedure. Am J Cardiol. 2005;96:1571–5.PubMedCrossRef
113.
Odegard KC, McGowan FX Jr, Zurakowski D, et al. Coagulation factor abnormalities in patients with single-ventricle physiology immediately prior to the Fontan procedure. Ann Thorac Surg. 2002;73:1770–7.PubMedCrossRef
114.
van Nieuwenhuizen RC, Peters M, Lubbers LJ, Trip MD, Tijssen JG, Mulder BJ. Abnormalities in liver function and coagulation profile following the Fontan procedure. Heart. 1999;82:40–6.PubMedPubMedCentralCrossRef
115.
Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85.PubMedCrossRef
116.
Varma C, Warr MR, Hendler AL, Paul NS, Webb GD, Therrien J. Prevalence of “silent” pulmonary emboli in adults after the Fontan operation. J Am Coll Cardiol. 2003;41:2252–8.PubMedCrossRef
117.
Deshaies C, Hamilton RM, Shohoudi A, et al. Thromboembolic risk after atriopulmonary, lateral tunnel, and extracardiac conduit Fontan surgery. J Am Coll Cardiol. 2019;74:1071–81.PubMedCrossRef
118.
Egbe AC, Connolly HM, McLeod CJ, et al. Thrombotic and embolic complications associated with atrial arrhythmia after Fontan operation: role of prophylactic therapy. J Am Coll Cardiol. 2016;68:1312–9.PubMedCrossRef
119.
Kawamatsu N, Ishizu T, Machino-Ohtsuka T, et al. Direct oral anticoagulant use and outcomes in adult patients with Fontan circulation: a multicenter retrospective cohort study. Int J Cardiol. 2021;327:74–9.PubMedCrossRef
120.
Al-Jazairi AS, Al Alshaykh HA, Di Salvo G, De Vol EB, Alhalees ZY. Assessment of late thromboembolic complications post-Fontan procedure in relation to different antithrombotic regimens: 30-years’ follow-up experience. Ann Pharmacother. 2019;53:786–93.PubMedCrossRef
121.
Iyengar AJ, Winlaw DS, Galati JC, et al. No difference between aspirin and warfarin after extracardiac Fontan in a propensity score analysis of 475 patients. Eur J Cardiothorac Surg. 2016;50:980–7.PubMedCrossRef
122.
123.
Michelson AD, Bhatt DL. How I use laboratory monitoring of antiplatelet therapy. Blood. 2017;130:713–21.PubMedCrossRef
124.
Li JS, Yow E, Berezny KY, et al. Dosing of clopidogrel for platelet inhibition in infants and young children. Circulation. 2008;117:553–9.PubMedCrossRef
Metadata
Title
Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient with Congenital Heart Disease
Authors
Eman Abdelghani
Clifford L. Cua
Jean Giver
Vilmarie Rodriguez
Publication date
01-12-2021
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2021
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-021-00228-4

Other articles of this Issue 2/2021

Cardiology and Therapy 2/2021 Go to the issue

Brief Report

Gender Disparities in Cardiology-Related COVID-19 Publications

Original Research

The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study

Original Research

Cardiac Complications in Pregnancy: A Systematic Review and Meta-Analysis of Diagnostic Accuracy of BNP and N-Terminal Pro-BNP

Review

Ischemic Stroke and Sleep: The Linking Genetic Factors

Original Research

Role of Pocket Ultrasound in Assessing Intravascular Volume to Guide Management in Heart Failure Patients with Renal Impairment

Correction

Correction to: Preoperative, Multidisciplinary Clinical Optimization of Patients with Severely Depressed Left Ventricular Ejection Fraction Who Are Undergoing Coronary Artery Bypass Grafting
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits